




RealRate

PHARMACEUTICAL 2014

Cormedix Inc
Rank 220 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cormedix Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cormedix Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 5.0% points. The greatest weakness of Cormedix Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 193% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	2,916
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,674
Liabilities, Non-Current	0
Other Assets	16
Other Compr. Net Income	0
Other Expenses	2,390
Other Liabilities	5,316
Other Net Income	-2,023
Other Revenues	-4.5
Property and Equipment	36
Research and Development	1,227
Selling, General and Administrative Expense	3,489

Output Variable	Value in 1000 USD
Assets	2,968
Liabilities	6,990
Expenses	7,106
Revenues	-4.5
Stockholders Equity	-4,022
Net Income	-9,133
Comprehensive Net Income	-9,133
BaseVar	9,546
ECR before LimitedLiability	-360%
Economic Capital Ratio	50%